Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine

Journal of Affective Disorders

Volumn 116, Issue 1-2, 2009, Pages 113-116

  Cooper Kazaz, Rena ^a   van der Deure, Wendy M ^b   Medici, Marco ^b   Visser, Theo J ^b   Alkelai, Ana ^a   Glaser, Benjamin ^a   Peeters, Robin P ^b   Lerer, Bernard ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Depression; Pharmacogenetics; Sertraline; Triiodothyronine; Type 1 deiodinase

Indexed keywords

DNA; LIOTHYRONINE; PLACEBO; SERTRALINE; THYROXINE DEIODINASE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DNA; DRUG THERAPY, COMBINATION; GENOTYPE; HUMANS; IODIDE PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SERTRALINE; THYROID FUNCTION TESTS; THYROTROPIN; TRIIODOTHYRONINE;

EID: 67349143128     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.10.019     Document Type: Article

References (14)

1. Altshuler L.L., Bauer M., Frye M.A., Gitlin M.J., Mintz J., Szuba M.P., Leight K.L., and Whybrow P.C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry 158 (2001) 1617-1622
2. Aronson R., Offman H.J., Joffe R.T., and Naylor C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry 53 (1996) 842-848
3. Bianco A.C., Salvatore D., Gereben B., Berry M.J., and Larsen P.R. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 23 (2002) 38-89
4. Canani L.H., Capp C., Dora J.M., Meyer E.L., Wagner M.S., Harney J.W., Larsen P.R., Gross J.L., Bianco A.C., and Maia A.L. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 90 (2005) 3472-3478
5. Cooper-Kazaz R., Apter J.T., Cohen R.T., Karagichev L., Muhammed-Moussa S., Grupper D., Drori T., Newman M.E., Sackeim H.A., Glaser B., and Lerer B. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 64 (2007) 679-688
6. Cooper-Kazaz R., and Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int. J. Neuropsychopharmacol. 11 (2008) 685-699 [Electronic Publication: Nov 30, 2007]
7. De Jong F.J., Peeters R.P., den Heijer T., van der Deure W.M., Hofman A., Uitterlinden A.G., Visser T.J., and Breteler M.M. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J. Clin. Endocrinol. Metab. 92 (2007) 636-640
8. Maia A.L., Dupuis J., Manning A., Liu C., Meigs J.B., Cupples L.A., Larsen P.R., and Fox C.S. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Thyroid 17 (2007) 199-202
9. Mentuccia D., Proietti-Pannunzi L., Tanner K., Bacci V., Pollin T.I., Poehlman E.T., Shuldiner A.R., and Celi F.S. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 51 (2002) 880-883
10. Peeters R.P., van Toor H., Klootwijk W., de Rijke Y.B., Kuiper G.G., Uitterlinden A.G., and Visser T.J. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J. Clin. Endocrinol. Metab. 88 (2003) 2880-2888
11. Peeters R.P., van den Beld A.W., van Toor H., Uitterlinden A.G., Janssen J.A., Lamberts S.W., and Visser T.J. A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans. J. Clin. Endocrinol. Metab. 90 (2005) 256-263
12. Peeters R.P., van den Beld A.W., Attalki H., Toor H., de Rijke Y.B., Kuiper G.G., Lamberts S.W., Janssen J.A., Uitterlinden A.G., and Visser T.J. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Amer. J. Physiol., Endocrinol. Metab. 289 (2005) E75-E81
13. Peeters R.P., van der Deure W.M., and Visser T.J. Genetic variation in thyroid hormone pathway genes: polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur. J. Endocrinol. 155 (2006) 655-662
14. Peeters R.P., van der Deure W.M., van den Beld A.W., van Toor H., Lamberts S.W., Janssen J.A., Uitterlinden A.G., and Visser T.J. The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. Clin. Endocrinol. 66 (2007) 808-815